For four decades, growth hormone therapy has meant one thing: a small injection, every night, for years. That routine is now being challenged — not by a new drug class, but by re-engineered versions of the same molecule designed to last a week. If you've been searching for "what is HGH", "HGH research" or "is HGH legal in Australia", this is the development worth understanding, because it changes the day-to-day reality of treatment far more than it changes the biology. Our full profile sits at /peptides/hgh.

What is HGH, and why daily dosing became the standard

Human growth hormone (somatropin) is a 191-amino-acid protein made by the anterior pituitary. Recombinant somatropin has been prescribed since the 1980s for defined conditions — paediatric growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature, chronic renal insufficiency in children, and adult growth hormone deficiency, among others.

Daily injection was never chosen for convenience. It was the only way to approximate a hormone that is normally released in pulses and cleared quickly. The trade-off is adherence: years of nightly needles in children and adolescents is a well-recognised weak point in this field, and the long-acting programs were built explicitly to address it.

The weekly shift: what the trials actually show

Three long-acting growth hormone (LAGH) products dominate the literature — lonapegsomatropin, somatrogon and somapacitan. Each uses a different engineering trick (a prodrug carrier, a peptide fusion, an albumin-binding modification) to stretch the same active hormone across seven days.

The headline result from the 52-week phase III programs in children is non-inferiority, not superiority: weekly dosing produced height velocity comparable to daily somatropin, with broadly similar reported safety over the trial period. That distinction matters. These products are not a more powerful growth hormone. They are the same hormone delivered less often, and the case for them rests on adherence and quality of life rather than better growth.

What is still unknown

  • Long-term safety is not settled. Weekly analogues produce a different pharmacokinetic profile to nightly dosing — sustained exposure rather than pulses. The 52-week trials cannot answer what decades of that pattern do.
  • Monitoring is harder. IGF-1 levels fluctuate across the weekly cycle, so the timing of a blood test changes the number. Clinicians have had to rewrite monitoring habits built around daily therapy.
  • Real-world data is early and thin. A two-year real-world report on somatrogon from a single Italian paediatric centre was published in early 2026 — useful, but a small, uncontrolled, single-site series is hypothesis-generating, not confirmatory.
  • Adult data lags paediatric data. Guidance on using somapacitan in adult growth hormone deficiency exists, but the adult evidence base is smaller and newer than the children's programs.

Is HGH legal in Australia? The regulatory reality

This is where Australian readers need to be precise. Somatropin is TGA-approved and available on the PBS, but only under tightly defined criteria — paediatric growth hormone deficiency and a short list of other conditions, assessed against strict growth and biochemical thresholds, with ongoing review. It is not subsidised, or approved, for ageing, body composition or athletic performance.

Somatropin is a Schedule 4 (prescription only) medicine and is border-controlled. Importing it without a valid prescription and the required permissions is illegal, and possession without a prescription is an offence. It is also on the WADA Prohibited List at all times, in and out of competition — a fact that catches recreational lifters and masters athletes off guard.

Which specific weekly products are registered on the ARTG and subsidised in Australia — and under what restrictions — changes over time and differs from the United States and European Union. Anyone actually being treated should confirm current status with their endocrinologist and the PBS schedule rather than relying on overseas coverage. For the wider regulatory picture across compounds, see /peptides.

Where the hype goes wrong

The "weekly HGH" headlines are already being borrowed by the grey market to sell something else entirely: growth-hormone-releasing peptides and "HGH boosters" that are not somatropin, not TGA-approved, and not supported by comparable trial evidence. Two points worth holding onto:

  1. The weekly products are regulated biologics for diagnosed deficiency. They are not a lifestyle upgrade.
  2. In healthy older adults, controlled trials of growth hormone have shown roughly 2 kg of lean mass gain, alongside real and consistent side effects — oedema, joint pain, carpal tunnel symptoms and worsened insulin resistance. Nothing about weekly dosing changes that risk–benefit calculation. Convenience does not create an indication.

Want the evidence-first version of every peptide story, without the sales pitch? Join the free updates list.

FAQ

What is HGH and what does somatropin actually do?

HGH is human growth hormone, a pituitary protein that drives growth in children and influences body composition and metabolism in adults. Somatropin is the recombinant (lab-made) version, prescribed to replace the hormone in people with diagnosed deficiency or specific growth disorders.

Is HGH legal in Australia?

Somatropin is TGA-approved and PBS-subsidised for defined conditions, but it is a Schedule 4 prescription-only, border-controlled medicine. Possessing or importing it without a valid prescription is illegal, and it is banned in sport by WADA at all times.

Are weekly growth hormone injections better than daily ones?

In 52-week phase III trials, weekly long-acting products matched daily somatropin on growth outcomes rather than beating them. The advantage is fewer injections and potentially better adherence, not stronger effect, and long-term safety data is still accumulating.

Does HGH work for anti-ageing or muscle gain?

Trials in healthy older adults found around 2 kg of lean mass gain, but with oedema, joint pain and increased insulin resistance, and no demonstrated functional or longevity benefit. It is not approved or subsidised in Australia for these uses.

Sources

This article is information only, not medical advice. Somatropin is TGA-approved and PBS-subsidised for defined conditions only and is a Schedule 4, border-controlled medicine; retatrutide.net.au is independent and does not sell or supply any compound.